Zoneddy Dayao, MD
Hematology & Oncology · Albuquerque, NMNPI 1124016084
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,590 of the $9,947 with a category attached, or 76.3%. 6 manufacturers reported payments, led by Gilead at 59.9% of the total. Reporting peaked in 2022 at $5,950 and has fallen 99.4% since, to $35 in 2025.
Across 31 payments — averaging $320.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Amgen$3K
- AstraZeneca$385
- Covis Pharma GmbH$200
- Pfizer$104
- Merck$16
Across 398 payments — averaging $777.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$284K
- Merck$22K
- Novartis$3K
What the payments were for
- Consulting fees$7,59076%
- Grants$3504%
- Travel & lodging$1,51215%
- Food & beverage$3984%
- Education$971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $5,962 |
| Amgen | 7 | $3,281 |
| AstraZeneca | 2 | $385 |
| Covis Pharma GmbH | 1 | $200 |
| Pfizer | 12 | $104 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,947 in reported general payments places this provider in the 75th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
- Bernard TawfikAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.